{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:59:30Z","timestamp":1793361570512,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering risk\u2013benefit ratio and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability to atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients complains and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving less side effects compared to 0.5% concentration.<\/jats:p>","DOI":"10.3390\/jcm12062314","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T03:14:35Z","timestamp":1678936475000},"page":"2314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions"],"prefix":"10.3390","volume":"12","author":[{"given":"Dovile","family":"Simonaviciute","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-2391","authenticated-orcid":false,"given":"Andrzej","family":"Grzybowski","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Warmia and Mazury, 10-724 Olsztyn, Poland"},{"name":"Institute for Research in Ophthalmology, 60-554 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-787X","authenticated-orcid":false,"given":"Carla","family":"Lanca","sequence":"additional","affiliation":[{"name":"Escola Superior de Tecnologia da Sa\u00fade de Lisboa (ESTeSL), Instituto Polit\u00e9cnico de Lisboa, 1549-020 Lisboa, Portugal"},{"name":"Comprehensive Health Research Center (CHRC), Escola Nacional de Sa\u00fade P\u00fablica, Universidade Nova de Lisboa, 1099-085 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Pui","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China"},{"name":"Joint Shantou International Eye Center of Shantou University, The Chinese University of Hong Kong, Shantou 515051, China"},{"name":"Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvydas","family":"Gelzinis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Zemaitiene","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, 44037 Kaunas, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10654-015-0010-0","article-title":"Prevalence of refractive error in Europe: The European Eye Epidemiology (E(3)) Consortium","volume":"30","author":"Williams","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2017.09.004","article-title":"The epidemics of myopia: Aetiology and prevention","volume":"62","author":"Morgan","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","article-title":"Updates of pathologic myopia","volume":"52","author":"Lai","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"Saw","year":"2005","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_6","first-page":"35","article-title":"Myopia: A growing global problem with sight-threatening complications","volume":"28","author":"Holden","year":"2015","journal-title":"Community Eye Health."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.clae.2012.08.046","article-title":"Predicted reduction in high myopia for various degrees of myopia control","volume":"35","author":"Brennan","year":"2012","journal-title":"Contact Lens Anterior Eye."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1167\/iovs.18-25221","article-title":"Prevention and Management of Myopia and Myopic Pathology","volume":"60","author":"Saw","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/opo.12305","article-title":"Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children","volume":"36","author":"Chua","year":"2016","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Saxena, R., Vashist, P., Tandon, R., Pandey, R.M., Bhardawaj, A., Gupta, V., and Menon, V. (2017). Incidence and progression of myopia and associated factors in urban school children in Delhi: The North India Myopia Study (NIM Study). PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189774"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI Prevention of Myopia and Its Progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_13","unstructured":"(2022, July 01). How to Use Low-Dose Atropine to Slow Myopic Progression in Kids-American Academy of Ophthalmology. Available online: https:\/\/www.aao.org\/eyenet\/article\/how-to-use-low-dose-atropine-to-slow-myopic-progre."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: A pilot study","volume":"41","author":"Joachimsen","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","article-title":"A multicenter Spanish study of atropine 0.01% in childhood myopia progression","volume":"11","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Myles, W., Dunlop, C., and McFadden, S.A. (2021). The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071444"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye"},{"key":"ref_22","first-page":"182","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","year":"2018","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","article-title":"Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops","volume":"44","year":"2021","journal-title":"J. Fran\u00e7ais D\u2019ophtalmologie"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial","volume":"50","author":"Lee","year":"2022","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00417-021-05254-5","article-title":"A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting","volume":"259","author":"Kaymak","year":"2021","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: A multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol","volume":"104","author":"Logan","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08164622.2022.2033603","article-title":"Symptoms and ocular findings associated with administration of 0.01% atropine in young adults","volume":"20","author":"Cyphers","year":"2022","journal-title":"Clin. Exp. Optom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/APO.0000000000000414","article-title":"Meta-Analysis Assessing Change in Pupillary Diameter, Accommodative Amplitude, and Efficacy of Atropine for Myopia Control","volume":"10","author":"Tran","year":"2021","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bjophthalmol-2015-307861","article-title":"The acceptability and visual impact of 0.01% atropine in a Caucasian population","volume":"100","author":"Loughman","year":"2016","journal-title":"Br. J. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:31Z","timestamp":1760122591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12062314"],"URL":"https:\/\/doi.org\/10.3390\/jcm12062314","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}